Demand for Contrast Media Injectors and Impact of COVID-19……..
The global contrast
media injectors market size is
expected to reach USD 1.4 billion by 2025,
growing at a CAGR of 5.8%, according
to a new report by Grand View Research, Inc. Rising demand for minimally
invasive surgical procedures is a major factor expected to boost the market
during the forecast period. These devices assist surgeons in accurate insertion
of contrast agents with reduced human errors, thus increasing the accuracy and
efficiency of surgical procedures. They play a crucial role in Intraoperative
Computed Tomography (iCT), Intraoperative Magnetic Resonance Imaging (iMRI),
and interventional cardiology. Availability of advanced injector systems for
diagnosis and intraoperative imaging has boosted adoption of these systems. For
instance, Medrad Stellant CT injection system integrated with Certegra
Workstation provides high efficiency and accuracy in CT imaging.
With Covid-19 infections rising globally, the
apprehension regarding a shortage of essential life-saving devices and other
essential medical supplies in order to prevent the spread of this pandemic and
provide optimum care to the infected also widens. In addition, till a
pharmacological treatment is developed, ventilators act as a vital treatment
preference for the COVID-19 patients, who may require critical care. Moreover,
there is an urgent need for a rapid acceleration in the manufacturing process
for a wide range of test-kits (antibody tests, self-administered, and others).
The report will account for Covid19 as a key market contributor.
Technological advancements, such as
automated contrast media injectors and double-head injectors, are also among
major factors supporting the growth of the market. Automated contrast media
injectors provide improved patient safety, accuracy, and enhance image quality.
Also, double-head injectors allow a large and rapid initial bolus of contrast,
which is required in several imaging procedures. For instance, in cardiac CT, a
fast injection is required for imaging of both sides of the ventricular septum
to identify septal thickness, shunts, and enlarged ventricles. Delivery of
contrast media is more efficient and controlled with a dual-head injector.
The
global contrast media injectors market size was estimated at USD 882.1 million
in 2016. Technological advancements and increasing demand for minimally
invasive surgeries are some of the major factors contributing to the market
growth.
To Request Sample Copy of this report, click the link:
Further Key Findings From the Report
Suggest:
·
CT injector systems segment was
the largest revenue-generating segment of the market in 2016 owing to
availability of technologically advanced products and their widespread
application for disease diagnosis and image-guided surgeries
·
The single head injectors
segment accounted for the largest revenue share in 2016 and is expected to
maintain its dominance throughout the study period
·
In the application segment,
interventional cardiology is projected grow at the highest rate during the
forecast period because of rising prevalence of cardiac diseases, such as
coronary artery disease, heart valve disease, and peripheral vascular disease
·
In 2016, hospitals dominated
the market in terms of revenue because of an increase in the number of hospital
admissions of patients suffering from cancer, neurological disorders, and
cardiovascular diseases
·
The North America contrast
media injectors market held the largest revenue share in 2016 and is projected
to maintain its dominance during the forecast period owing to well-established
healthcare infrastructure
·
Some of the major players are
Bayer HealthCare LLC; Guerbet Group; Bracco Group; Medtron AG; GE Healthcare;
Nemoto Kyorindo Co., Ltd.; Ulrich GmbH & Co. KG; VIVID IMAGING; Sino
Medical-Device Technology Co., Ltd.; and APOLLO RT Co. Ltd.
Technological
advancements in the field of contrast media injectors, including IT-enabled
solutions for syringeless, dual-head, and automated injectors, have brought
about incremental changes in medical imaging. Syringeless injectors are more
user-friendly, efficient, minimize contrast agent wastage, and provide contrast
enhancement during imaging. For instance, in November 2016, Bracco Group
launched a new syringeless injector CT Exprès 3D Contrast Media Delivery System
in the U.S. This system provides several advantages, such as doing away with
the need to fill and clean syringes, user-friendliness, and high efficiency.
Minimally
invasive surgical procedures provide various advantages, such as smaller
incisions, rapid wound healing, shorter hospital stays, less pain, and minor
surgical wounds. Minimally invasive surgical procedures with contrast media
injectors deliver high quality real-time imaging of the surgical site, and
ensure that surgeons are treating the appropriate area. Thus, adoption of these
products for minimally invasive surgeries is rising gradually, and this is
expected to fuel growth.
Increase
in prevalence of several chronic diseases, such as cancer, as well as cardiac,
neurological, and orthopedic diseases, is expected to boost the market.
According to American Cancer Society, around 1,688,780 new cancer cases are
estimated to be diagnosed in 2017 in the U.S. Furthermore, according to CDC,
28.4 million adults were diagnosed with heart disease in the U.S. in 2015.
Thus, there is growing demand for advanced products for diagnosis and treatment
of chronic diseases, which is projected to drive growth.
Browse
Press Release of this report:
Grand View Research has segmented the
global contrast media injectors market on the basis of product, type,
application, end use, and region:
Contrast Media Injectors Product Outlook (Revenue, USD
Million; 2014 - 2025)
·
Injector Systems
o CT injector systems
o MRI injector systems
o Cardiovascular/angiography injector systems
·
Consumables
o Tubing
o Syringe
o Others
Contrast Media Injectors Type Outlook (Revenue, USD
Million; 2014 - 2025)
·
Single Head Injectors
·
Dual-Head Injectors
·
Syringeless Injectors
Contrast Media Injectors Application Outlook (Revenue,
USD Million; 2014 - 2025)
·
Radiology
·
Interventional Cardiology
·
Interventional Radiology
Contrast Media Injectors End-Use Outlook (Revenue, USD
Million; 2014 - 2025)
·
Hospitals
·
Diagnostics Centers
·
Ambulatory Surgery Centers
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Comments
Post a Comment